FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020953967> ?p ?o ?g. }

• W2020953967 endingPage "1176" @default.
• W2020953967 startingPage "1170" @default.
• W2020953967 abstract "Summary Budesonide is a glucocorticosteroid with a local anti‐inflammatory effect. Coeliac disease is an immune‐mediated disease caused by gluten ingestion in intolerant patients. The aim of the present study was to investigate the efficacy of budesonide in malabsorptive coeliac patients and its effect in an in vitro gliadin challenge. Twenty coeliac patients with malabsorption were enrolled in the present study and were randomly assigned to one of two 4 week treatments: (i) a gluten‐free diet alone; or (ii) a gluten‐free diet plus 6 mg budesonide daily. At the end of 4 weeks treatment, all patients underwent clinical evaluation, laboratory tests and self‐evaluation of well‐being using a visual analogue scale. Intestinal biopsies from five coeliac patients (selected randomly) and four non‐coeliac disease controls who underwent upper endoscopy for intestinal bleeding were challenged with gliadin (0.5 mg/mL) and budesonide (10–30 µg/mL) for 3 and 24 h. Biopsies were tested by immunohistochemistry and immunofluorescence for known markers of inflammation. Treatment of patients with 6 mg budesonide daily for 4 weeks resulted in increased bodyweight, a decreased number of evacuations and decreased stool weight compared with patients on a gluten‐free diet alone for 4 weeks. Well‐being scores were higher in patients treated with both a gluten‐free diet and budesonide compared with those receiving a gluten‐free diet alone. In vitro studies showed that budesonide reduced epithelial tyrosine phosphorylation and expression of histocompatibility leucocyte antigen complex DR (HLA‐DR) elicited by gliadin‐derived peptides. In addition, the expression of cyclo‐oxygenase (COX)‐2 and intercellular adhesion molecule (ICAM)‐1 in the lamina propria was reduced in patients treated with both gliadin and budesonide compared with patients treated with gliadin alone. Budesonide alone decreased HLA‐DR in crypt enterocytes, as well as ICAM‐1 and COX‐2 expression in the lamina propria of biopsy specimen of coeliac patients. Budesonide had no effect in control samples. In conclusion, the results of the present study indicate that budesonide shows efficacy in the treatment of symptoms in adult coeliac patients with overt malabsorption. The mechanism underlying the effects of budesonide in reducing symptoms was elucidated by in vitro studies involving a gliadin challenge." @default.
• W2020953967 created "2016-06-24" @default.
• W2020953967 creator A5009768907 @default.
• W2020953967 creator A5020182729 @default.
• W2020953967 creator A5040159293 @default.
• W2020953967 creator A5044275230 @default.
• W2020953967 creator A5048967540 @default.
• W2020953967 creator A5070062674 @default.
• W2020953967 creator A5080194788 @default.
• W2020953967 creator A5088927856 @default.
• W2020953967 creator A5090631485 @default.
• W2020953967 creator A5091301533 @default.
• W2020953967 date "2009-11-25" @default.
• W2020953967 modified "2023-10-18" @default.
• W2020953967 title "Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: An<i>in vivo</i>/<i>in vitro</i>pilot study" @default.
• W2020953967 cites W1426259424 @default.
• W2020953967 cites W1968297741 @default.
• W2020953967 cites W1973741860 @default.
• W2020953967 cites W1975749919 @default.
• W2020953967 cites W1981788459 @default.
• W2020953967 cites W1993330227 @default.
• W2020953967 cites W2015411480 @default.
• W2020953967 cites W2017489436 @default.
• W2020953967 cites W2027812459 @default.
• W2020953967 cites W2035117443 @default.
• W2020953967 cites W2036798664 @default.
• W2020953967 cites W2039051328 @default.
• W2020953967 cites W2048279095 @default.
• W2020953967 cites W2059761425 @default.
• W2020953967 cites W2064069118 @default.
• W2020953967 cites W2066019144 @default.
• W2020953967 cites W2071323350 @default.
• W2020953967 cites W2078710292 @default.
• W2020953967 cites W2086150474 @default.
• W2020953967 cites W2098567963 @default.
• W2020953967 cites W2101919416 @default.
• W2020953967 cites W2105377863 @default.
• W2020953967 cites W2117998107 @default.
• W2020953967 cites W2134304452 @default.
• W2020953967 cites W2139864287 @default.
• W2020953967 cites W2150998085 @default.
• W2020953967 cites W2171045789 @default.
• W2020953967 cites W2247854797 @default.
• W2020953967 cites W2315020282 @default.
• W2020953967 cites W2340424973 @default.
• W2020953967 cites W2401039545 @default.
• W2020953967 cites W4294305087 @default.
• W2020953967 doi "https://doi.org/10.1111/j.1440-1681.2009.05211.x" @default.
• W2020953967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19473192" @default.
• W2020953967 hasPublicationYear "2009" @default.
• W2020953967 type Work @default.
• W2020953967 sameAs 2020953967 @default.
• W2020953967 citedByCount "36" @default.
• W2020953967 countsByYear W20209539672012 @default.
• W2020953967 countsByYear W20209539672014 @default.
• W2020953967 countsByYear W20209539672015 @default.
• W2020953967 countsByYear W20209539672016 @default.
• W2020953967 countsByYear W20209539672017 @default.
• W2020953967 countsByYear W20209539672018 @default.
• W2020953967 countsByYear W20209539672019 @default.
• W2020953967 countsByYear W20209539672020 @default.
• W2020953967 countsByYear W20209539672021 @default.
• W2020953967 countsByYear W20209539672022 @default.
• W2020953967 countsByYear W20209539672023 @default.
• W2020953967 crossrefType "journal-article" @default.
• W2020953967 hasAuthorship W2020953967A5009768907 @default.
• W2020953967 hasAuthorship W2020953967A5020182729 @default.
• W2020953967 hasAuthorship W2020953967A5040159293 @default.
• W2020953967 hasAuthorship W2020953967A5044275230 @default.
• W2020953967 hasAuthorship W2020953967A5048967540 @default.
• W2020953967 hasAuthorship W2020953967A5070062674 @default.
• W2020953967 hasAuthorship W2020953967A5080194788 @default.
• W2020953967 hasAuthorship W2020953967A5088927856 @default.
• W2020953967 hasAuthorship W2020953967A5090631485 @default.
• W2020953967 hasAuthorship W2020953967A5091301533 @default.
• W2020953967 hasConcept C126322002 @default.
• W2020953967 hasConcept C142724271 @default.
• W2020953967 hasConcept C203014093 @default.
• W2020953967 hasConcept C2776136866 @default.
• W2020953967 hasConcept C2776336767 @default.
• W2020953967 hasConcept C2776804153 @default.
• W2020953967 hasConcept C2779134260 @default.
• W2020953967 hasConcept C2780092158 @default.
• W2020953967 hasConcept C2780349322 @default.
• W2020953967 hasConcept C2780439177 @default.
• W2020953967 hasConcept C71924100 @default.
• W2020953967 hasConcept C90924648 @default.
• W2020953967 hasConceptScore W2020953967C126322002 @default.
• W2020953967 hasConceptScore W2020953967C142724271 @default.
• W2020953967 hasConceptScore W2020953967C203014093 @default.
• W2020953967 hasConceptScore W2020953967C2776136866 @default.
• W2020953967 hasConceptScore W2020953967C2776336767 @default.
• W2020953967 hasConceptScore W2020953967C2776804153 @default.
• W2020953967 hasConceptScore W2020953967C2779134260 @default.
• W2020953967 hasConceptScore W2020953967C2780092158 @default.
• W2020953967 hasConceptScore W2020953967C2780349322 @default.
• W2020953967 hasConceptScore W2020953967C2780439177 @default.
• W2020953967 hasConceptScore W2020953967C71924100 @default.

• next